La titularidad de los derechos patrimoniales de esta obra pertenece a las instituciones editoras. Su uso se rige por una licencia Creative Commons BY-NC-ND 4.0 Internacional, https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode.es, para un uso diferente consultar al responsable jurídico del repositorio por medio del correo electrónico arevalor@unam.mx.
Ver términos de la licencia
División de Estudios de Posgrado, Facultad de Medicina, UNAM
Revista
Repositorio
Contacto
Revistas UNAM. Dirección General de Publicaciones y Fomento Editorial, UNAM en revistas@unam.mx
Autor(es)
Ramos Mejía, Ana Karen; Alvarado Gutiérrez, Teresa
Tipo
Artículo de Investigación
Área del conocimiento
Medicina y Ciencias de la Salud
Título
Therapeutic Adherence in Type 2 Diabetes Patients Treated with Metformin and Sitagliptin
Fecha
2024-03-20
Resumen
Objective: to estimate therapeutic adherence in patients with type 2 diabetes who have initiated combination therapy based on sitagliptin with metformin. Methods: an analytical cross-sectional study where the sample size consisted of 320 patients, obtained using the formula for finite proportions by non-randomized sampling by quotas. During the period from March to September 2022, therapeutic adherence was evaluated in patients who initiated sitagliptin therapy with metformin using the MMAS-8 scale. Descriptive statistics were used to analyze qualitative variables, such as frequencies and percentages, and quantitative variables were measured for central tendency and dispersion. Inferential statistics were analyzed using X2. Results: 55.6% of the patients had average therapeutic adherence. The analysis found no statistically significant association between gender and therapeutic adherence (p= 0.796). Most participants with basic education had medium therapeutic adherence, and there were no significant differences between the levels of schooling (p= 0.89). Comorbidities were present in 80.9% of the participants, with a predominance of medium therapeutic adherence, but no significant association was found (p= 0.620). Conclusion: the therapeutic adherence was only moderate. Improving adherence is a significant challenge for healthcare professionals, and further research should be conducted to optimize the management of chronic diseases.
Tema
Medication Adherence; Diabetes Mellitus; Type 2; Metformin; Dipeptidyl-Peptidase IV Inhibitor; Adherencia terapéutica; Diabetes mellitus tipo 2; Metformina; Inhibidor de la dipeptidil-peptidasa IV
Idioma
spa
ISSN
ISSN electrónico: 1405-8871
